Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Health Systems Can Lower Operational Costs and Reduce Environmental Impact with CareAdvantage from the Johnson & Johnson Medical Devices Companies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:32pm CET

By a News Reporter-Staff News Editor at Ecology, Environment & Conservation -- With health systems focused on finding new ways to address their impact on the environment and reduce costs, CareAdvantage from the Johnson & Johnson Medical Devices Companies* now has a new Sustainability capability. Designed to help health systems achieve specific environmental, waste management, cost savings, and sustainable purchasing goals, this offering from the Johnson & Johnson Medical Devices Companies (JJMDC)* * draws on more than 25 years of sustainability commitments by the Johnson & Johnson Family of Companies, including its leadership in medical device reprocessing and its deep commitment to its Health for Humanity 2020 Goals.

There is a growing demand for sustainability strategies in the healthcare ecosystem among U.S. health system executives and operating room clinicians, according to insights from a new JJMDC survey, called the Voices for Value Insights Seriesii. The survey found that nine out of 10 clinicians (92%) and health system executives (88%) agree that sustainability provides long-term cost savings. The majority also agree that sustainability provides additional benefits, such as protecting the environment (76%), improving patient care (73%), and increasing the ability to manage risk and regulatory performance (68%). Nearly all (95%) believe that environmental sustainability contributes to the value of care delivered in their health system. The survey was conducted online between September 7 and 13, 2017 among 92 executives and clinicians at large U.S. health systems.

"Sustainability is critically important to Intermountain Healthcare, but recycling alone is not going to help us reach our goals," said Steve Bergstrom, Director of Sustainability at Intermountain Healthcare. "Our collaboration helps us reduce waste and operating room expenses through a more circular systems approach that is saving hundreds of thousands of dollars on medical device costs and diverting tens of thousands of pounds of Intermountain waste from landfills each year."

The CareAdvantage Sustainability capability enables best-in-class reprocessing across a broad spectrum of product categories, to include both JJMDC as well as non-JJMDC reprocessed single-use devices. It also includes practical tools and educational resources to help health systems create sustainability programs with financial and environmental benefits while implementing best practices for measuring and communicating the value of sustainability in healthcare.

The CareAdvantage Sustainability capability can also help purchasing and sustainability teams in healthcare delivery systems meet their Environmental Preferable Purchasing (EPP) goals. Specific expertise is designed to help healthcare delivery systems build a consistent approach to EPP assessments. In addition, through EARTHWARDS®, the Johnson & Johnson approach for encouraging the development of more sustainable products, health systems can access devices which have been designed with factors such as reducing materials, minimizing packaging, and reducing energy usage in mind.

"Drawing on our extensive experience in sustainability, we can provide health systems with a broad portfolio of sustainably sourced medical devices to help them meet their commitment to environmental stewardship efficiently and cost effectively," said Melinda Thiel, Vice President, Customer Marketing & Solutions at JJMDC. "This is just one element of how we approach customer needs, which starts with listening and leads to a holistic, tailored approach to help them reach their goals and deliver measurable results."

For more information about CareAdvantage and its capabilities, including Sustainability, visit www.careadvantagejjmdc.com. Join the discussion about value-based care on Voices for Value on LinkedIn.

Keywords for this news article include: Environment, Johnson & Johnson Medical Devices Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Science Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/15 JOHNSON & JOHNSON : ordered to pay $15M in vaginal mesh case
12/15 CONSUMERS ENERGY : Newsweek Ranks Consumers Energy as #1 Company in Michigan in ..
12/15 JOHNSON & JOHNSON : Jury awards $15 million in j&j trial
12/15 JOHNSON & JOHNSON : Janssen and Leading Advocacy Organizations Introduce Cancer...
12/14 JOHNSON & JOHNSON : Los Alamos research fundamental to first efficacy study for ..
12/14 JOHNSON & JOHNSON : Innovation Announces Launch of JLABS @ Shanghai in Collabora..
12/14 JOHNSON & JOHNSON : Bergen jury gets pelvic mesh case
12/14 JOHNSON & JOHNSON : and 4mm Navigational Bi-Directional Ablation catheters
12/14 JOHNSON & JOHNSON : J&Js Darzalex shows promise in newly-diagnosed multiple myel..
12/14 JOHNSON & JOHNSON : J&J`s Darzalex cuts risk of disease progression and death by..
More news
News from SeekingAlpha
12/15 Just Turned 40? How To Reach A Goal Of $1.5 Million.
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 Let Hitters Swing For The Fence
12/14 The Next 20 Dividend Achievers Absolutely Trounce The Market
12/14 Johnson & Johnson (JNJ) Presents at BMO Capital Markets Prescriptions for Suc..
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,35%
P/E ratio 2017 23,89
P/E ratio 2018 19,64
EV / Sales 2017 5,24x
EV / Sales 2018 4,83x
Capitalization 383 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON22.95%382 722
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759
AMGEN21.32%126 976